Specific niche view of the structured sector hierarchy. Useful for precedent work where broader sector slices include too much noise.
| Target | Buyer / Investor | Sector | Geo | Transaction size | EV / EBITDA |
|---|---|---|---|---|---|
| Silence Therapeutics | Merck | Bio Therapeutic Drugs | $1,300M | n/m | |
| AtaiBeckley Inc. | Eli Lilly and Company | Bio Therapeutic Drugs | $3,800M | n/m | |
| Silence Therapeutics | Merck KGaA, Darmstadt, Germany | Bio Therapeutic Drugs | $1,300M | n/m | |
| Biosergen AB | Flerie AB | Bio Therapeutic Drugs | $18.0M – $24.0M | n/m | |
| Biosergen | Flerie | Bio Therapeutic Drugs | $18.0M – $24.0M | n/m | |
| Acceleron | Merck | Bio Therapeutic Drugs | $11,500M | n/m | |
| Firefly Bio, Inc. | Johnson & Johnson | Bio Therapeutic Drugs | $340M – $460M | n/m | |
| Abogen Biosciences | Novartis | Bio Therapeutic Drugs | $7,800M | n/m | |
| IntraBio Inc. | Shionogi & Co., Ltd. | Bio Therapeutic Drugs | $2,000M | n/m | |
| Werewolf Therapeutics | Ambros Therapeutics | Bio Therapeutic Drugs | $750M | n/m |
Bins are observed deal frequencies across disclosed transactions. Use as a directional reference, not a target valuation.
Use the directory on the recent deals hub to switch between countries, sectors and sub-sectors. A free account unlocks the structured filters that go beyond the public view.